187 institutions hold shares in Rhythm Pharmaceuticals Inc. (RYTM), with 1.51M shares held by insiders accounting for 3.00% while institutional investors hold 88.30% of the company’s shares. The shares outstanding are 44.22M, and float is at 36.86M with Short Float at 11.30%. Institutions hold 85.65% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is NEA Management Company, LLC with over 4.91 million shares valued at $146.04 million. The investor’s holdings represent 9.79% of the RYTM Shares outstanding. As of Dec 30, 2020, the second largest holder is Janus Henderson Group PLC with 4.49 million shares valued at $133.54 million to account for 8.95% of the shares outstanding. The other top investors are Primecap Management Company which holds 4.34 million shares representing 8.65% and valued at over $129.1 million, while RA Capital Management, L.P. holds 8.33% of the shares totaling 4.18 million with a market value of $124.24 million.
Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) is -30.64% lower on its value in year-to-date trading and has touched a low of $17.27 and a high of $43.26 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RYTM stock was last observed hovering at around $20.38 in the last trading session, with the day’s gains setting it 0.24% off its average median price target of $47.50 for the next 12 months. It is also 65.63% off the consensus price target high of $60.00 offered by 8 analysts, but current levels are 10.35% higher than the price target low of $23.00 for the same period.
Currently trading at $20.62, the stock is -2.57% and -16.95% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.28 million and changing 1.18% at the moment leaves the stock -19.01% off its SMA200. RYTM registered 12.49% gain for a year compared to 6-month gain of -11.80%. The firm has a 50-day simple moving average (SMA 50) of $25.17 and a 200-day simple moving average (SMA200) of $26.95.
The stock witnessed a -19.04% loss in the last 1 month and extending the period to 3 months gives it a -41.27%, and is -0.63% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.51% over the week and 6.41% over the month.
Distance from 52-week low is 19.40% and -52.33% from its 52-week high.
Rhythm Pharmaceuticals Inc. (RYTM) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Rhythm Pharmaceuticals Inc. (RYTM) is a “Overweight”. 8 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Rhythm Pharmaceuticals Inc. is expected to release its quarterly report on 08/10/2021 and quarterly earnings per share for the current quarter are estimated at $0.45 with sales reaching $59.82M over the same period.The EPS is expected to grow by 21.40% this year.
Rhythm Pharmaceuticals Inc. (RYTM) Insider Activity
A total of 9 insider transactions have happened at Rhythm Pharmaceuticals Inc. (RYTM) in the last six months, with sales accounting for 7 and purchases happening 2 times. The most recent transaction is an insider purchase by Meeker David P, the company’s President and CEO. SEC filings show that Meeker David P bought 10,000 shares of the company’s common stock on Mar 30 at a price of $20.17 per share for a total of $0.2 million. Following the purchase, the insider now owns 0.11 million shares.
Rhythm Pharmaceuticals Inc. disclosed in a document filed with the SEC on Mar 15 that Foley Todd (Director) sold a total of 1,000,000 shares of the company’s common stock. The trade occurred on Mar 15 and was made at $25.10 per share for $25.1 million. Following the transaction, the insider now directly holds 0.91 million shares of the RYTM stock.
Still, SEC filings show that on Dec 03, RA CAPITAL MANAGEMENT, L.P. (Former 10% Owner) disposed off 207,604 shares at an average price of $29.03 for $6.03 million. The insider now directly holds 4,360,860 shares of Rhythm Pharmaceuticals Inc. (RYTM).
Rhythm Pharmaceuticals Inc. (RYTM): Who are the competitors?
The company’s main competitors (and peers) include Pieris Pharmaceuticals Inc. (PIRS) that is trading -11.07% down over the past 12 months. Short interest in the company’s stock has fallen -51.82% from the last report on Mar 30, 2021 to stand at a total of 4.16 million short shares sold with a short interest ratio of 8.28.